A. Tuba Kendi

Quantitative ⁶⁸Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following ¹⁷⁷Lu-PSMA-617 (VISION Trial)

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors

Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial

A VISION Substudy of Reader Agreement on⁶⁸Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for¹⁷⁷Lu-PSMA-617 Radioligand Therapy

ACR Appropriateness Criteria® Lower Extremity Chronic Venous Disease

[⁶⁸Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [¹⁷⁷Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.

ACR Appropriateness Criteria® Head Trauma: 2021 Update

ACR Appropriateness Criteria® Plexopathy: 2021 Update

ACR Appropriateness Criteria® Myelopathy: 2021 Update

ACR Appropriateness Criteria® Thoracic Outlet Syndrome

ACR Appropriateness Criteria® Seizures and Epilepsy

ACR Appropriateness Criteria® Acute Mental Status Change, Delirium, and New Onset Psychosis

ACR Appropriateness Criteria® Clinically Suspected Vascular Malformation of the Extremities

ACR Appropriateness Criteria® Management of Vertebral Compression Fractures

ACR Appropriateness Criteria® Hearing Loss and/or Vertigo

Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study.

ACR Appropriateness Criteria Head Trauma